Model Can Predict Postoperative RT Delay in Head & Neck Cancer
MONDAY, April 24, 2023 -- A model incorporating individual-level factors with health literacy and community-level factors predicts postoperative radiation therapy (PORT) delay for patients with head and neck squamous cell carcinoma (HNSCC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2023 Category: Pharmaceuticals Source Type: news
Light-to-moderate Alcohol Consumption and Progressive NAFLD Light-to-moderate Alcohol Consumption and Progressive NAFLD
This systemic review aimed to determine the impact of light-to-moderate alcohol use on the progression of NAFLD to NASH, fibrosis, cirrhosis and hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
7 Myths About Kidney Cancer, Debunked
Kidney cancer may well be the least-known common cancer in the U.S. An estimated 81,800 new cases will be diagnosed this year, according to the American Cancer Society. In 2022, the disease was the eighth most common cancer, occurring more frequently than leukemia and thyroid cancer. Yet, when people are diagnosed, their reaction is often, “I didn’t even know you could get cancer of the kidneys,” says Dr. Alice C. Fan, an assistant professor of medicine in the division of oncology at Stanford University School of Medicine in Palo Alto, Calif.
Humans have two fist-sized kidneys (shaped like the eponymous b...
Source: TIME: Health - April 19, 2023 Category: Consumer Health News Authors: Katherine Hobson Tags: Uncategorized Cancer healthscienceclimate Source Type: news
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
(MedPage Today) -- ORLANDO -- An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 19, 2023 Category: Hematology Source Type: news
AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
TUESDAY, April 18, 2023 -- For patients with high-risk hepatocellular carcinoma (HCC), adjuvant therapy of atezolizumab with bevacizumab (atezo + bev) prolongs recurrence-free survival, according to a study presented at the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2023 Category: Pharmaceuticals Source Type: news
Adjuvant Combo May Change Practice in High-Risk Liver Cancer
(MedPage Today) -- ORLANDO -- For the first time, adjuvant therapy has improved recurrence-free survival (RFS) after surgery or ablation for hepatocellular carcinoma (HCC), the most common type of liver cancer, according to the randomized IMbrave050... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 17, 2023 Category: Gastroenterology Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Immunotherapy in HCC: Influence of Underlying Liver Disease Immunotherapy in HCC: Influence of Underlying Liver Disease
A new review looks at the potential impacts of liver disease on the efficacy of immunotherapy in patients with hepatocellular carcinoma.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
ChatGPT May Help Patients Better Understand Cirrhosis, Liver Cancer
(MedPage Today) -- Generative artificial intelligence (AI) chatbot ChatGPT may be helpful for delivering some medical information to patients with cirrhosis or hepatocellular carcinoma (HCC), according to an analysis of AI-generated answers to... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 6, 2023 Category: Gastroenterology Source Type: news
Post-Immunotherapy Combo Promising in Advanced RCC
(MedPage Today) -- Combination treatment with a hypoxia-inducible factor (HIF) 2α inhibitor and tyrosine kinase inhibitor induced responses in nearly a third of advanced renal cell carcinoma (RCC) patients previously treated with immunotherapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 3, 2023 Category: Hematology Source Type: news
FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma
On April 3, 2023, the Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas Pharma) with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 3, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, inve...
Source: Johnson and Johnson - March 29, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
DCISionRT(R) by PreludeDx(TM) Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare and Medicaid Services
LAGUNA HILLS, Calif., March 28, 2023 -- (Healthcare Sales & Marketing Network) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Med... Diagnostics, Oncology PreludeDx, DCISionRT test, ductal carcinoma in situ (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2023 Category: Pharmaceuticals Source Type: news
